不同基因型HCV及HCV、HBV重叠感染者对α-干扰素联合利巴韦林及胸腺肽治疗反应的比较

To Study on the response to combined α-IFN, ribavilin and thymosin α 1 for different types HCV infection and HCV-HBV coinfection. Genotypes of HCV in 171 patients with HCV infection and HCV-HBV coinfection were investigated and the patients were treated with IFN+ribavilin, curative effect of IFN+ribavilin to different type HCV infection, HCV-HBV coinfection and the response of HCV-Ⅱ/1b to IFN+ribavilin+Thymosin αl theapy were analyzed. The response rates in the four types HCV infection were different, HCV-Ⅳ/2b was the highest (57.78%) , HCV-Ⅱ/1b was the lowest (11.76%) . The response rate in those patients with HCV-Ⅱ/1b infection who treated with Thymosin αl was 46.15%, higher than those without Thymosinαl group, P<0.05;and the complete response rate was 30.76%, showed significant difference compared with the latter. In patients with HCV-HBV coinfection, the response rate to IFN+ribavilin was 11.11%, HCV Ⅱ/1b displayed the lowest response than other types when it infection alone, and presented more lower response when coinfected with HBV. The response rate could be raised if Thymosinα 1 were added.